Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mupirocin + chlorhexidine is a topical combination therapy used primarily for the decolonization and treatment of skin infections, especially those caused by *Staphylococcus aureus*, including methicillin-resistant strains (MRSA). Mupirocin is a naturally occurring antibiotic produced by *Pseudomonas fluorescens* that inhibits bacterial protein synthesis by specifically and reversibly binding to bacterial isoleucyl-tRNA synthetase, leading to inhibition of protein and RNA synthesis. Chlorhexidine is an antiseptic with broad-spectrum antimicrobial activity; it disrupts microbial cell membranes through interaction with negatively charged phosphate groups on the cell surface, causing leakage of intracellular material and ultimately cell death. This combination is often used in clinical settings for infection control and prevention strategies such as MRSA decolonization[1][3][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mupirocin + chlorhexidine.